Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Next Potential Big ADC Player? Korean Firms Take It Up A Notch

Most Assets Still Early Stage

Executive Summary

Scrip takes a look at the increasingly competitive landscape of Korean antibody-drug conjugate developers, which are now vying to catch up with their global rivals in the hot area.

You may also be interested in...



Korean Industry Demands Bold Support Amid US Policy Moves

As the global biopharma industry attempts to understand the implications of the US Inflation Reduction Act, South Korea's biopharma industry is pressing its government to come up with "bold and rapid" additional measures to reduce the possible negative impact of the legislation and other US policies with international implications, and to support the sector amid generally rising global competition.

The Hunt For Big Fish: How KDDF Is Helping Create Korean Deals

Korea Drug Development Fund CEO H. Samuel Muk talks to Scrip how the government agency has evolved to support the Korean biopharma industry’s R&D and business development activities, as well as what key new projects are underway.

Korea’s Key Words For 2023: Regulatory Innovation, Digital Healthcare

The Pink Sheet’s roundup of key regulatory issues in Korea for 2022 and outlook for this year.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC147659

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel